Top Biopharma Company Adopts BioFortis' Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data

COLUMBIA, Md., Sept. 10 A top 5 bio-pharmaceutical companyhas licensed BioFortis' Labmatrix(TM) software for use enterprise-wide, acrossmultiple therapeutic areas within its global Translational Medicineorganization, BioFortis officials announced today. This largebiopharmaceutical company decided to adopt the Labmatrix technology after anextensive review process that included a pilot by end users and the researchinformatics division. The company expects full implementation of Labmatrix tohave a rapid and profound effect on the productivity of its TranslationalMedicine efforts.

"Labmatrix is the only data management and exploration application on themarket that is built from the ground up to support translational medicine andbiomarker discovery," said Jian Wang, BioFortis President and CEO. "There isa growing need in the biotechnology and pharmaceutical industry for robustinformatics systems in the translational medicine space. This agreementdemonstrates BioFortis' leadership position in fulfilling such needs," Dr.Wang concluded.

Labmatrix, an enterprise translational research information managementsoftware product, will be used to support Translational Medicine initiativesassociated with research programs, clinical trials, and longitudinal clinicalstudies conducted with external collaborators.

About BioFortis

BioFortis is a privately-held company focused on providing biomedicalresearch software and services to the life sciences sector, includinggovernment and academic research institutes and the biopharmaceuticalindustry. BioFortis' flagship product Labmatrix(TM) supports translationalmedicine initiatives with applications in clinical research, biobanking andbiomarker discovery. Labmatrix enables transparent data management,integration, collaboration and compliance to privacy regulations.

SOURCE BioFortis

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...